Strides Pharma gets USFDA nod for generic medication
Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
Singapore-based Strides Pharma Global Pte Ltd has received approval for Levetiracetam Oral Solution USP, 100 mg/mL, from the US Food & Drug Administration (USFDA), the company said in a regulatory filing.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Keppra Oral Solution of UCB, Inc, it added.
It is used in the treatment of seizures.
As per IQVIA data, the Levetiracetam Oral Solution has a market size of USD 55 million.
The product will be manufactured at the company's facility in Bengaluru, the drug firm said.
The company said it now has 260 cumulative abbreviated new drug application (ANDA) filings with the USFDA, of which over 230 filings have been approved.
The company said it has set a target to launch 60 new products over three years in the US.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
IPL Auction 2025 Free Live Streaming: When and where to watch Indian Premier League 2025 mega auction live online, on TV, Mobile Apps, and Laptop?
Tamil Nadu Weather Alert: Chennai may receive heavy rains; IMD issues yellow & orange alerts in these districts
SIP vs PPF: How much corpus you can build in 15 years by investing Rs 1.5 lakh per year? Understand through calculations
SIP+SWP: Rs 10,000 monthly SIP for 20 years, Rs 25 lakh lump sum investment, then Rs 2.15 lakh monthly income for 25 years; see expert calculations
SBI Senior Citizen Latest FD Rates: What senior citizens can get on Rs 7 lakh, Rs 14 lakh, and Rs 21 lakh investments in Amrit Vrishti, 1-, 3-, and 5-year fixed deposits
12:22 PM IST